130 related articles for article (PubMed ID: 35584167)
1. Nivolumab in Esophageal Squamous-Cell Carcinoma.
Abushukair H; Abushukair A; Saeed A
N Engl J Med; 2022 May; 386(20):1959. PubMed ID: 35584167
[No Abstract] [Full Text] [Related]
2. Nivolumab in Esophageal Squamous-Cell Carcinoma.
Wu T
N Engl J Med; 2022 May; 386(20):1959-1961. PubMed ID: 35584168
[No Abstract] [Full Text] [Related]
3. Nivolumab in Esophageal Squamous-Cell Carcinoma.
Ozer M; Sahin I
N Engl J Med; 2022 May; 386(20):1958-1959. PubMed ID: 35584166
[No Abstract] [Full Text] [Related]
4. Nivolumab in Esophageal Squamous-Cell Carcinoma. Reply.
Kato K; Lei M
N Engl J Med; 2022 May; 386(20):1961. PubMed ID: 35584169
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.
Zhang PF; Xie D; Li Q
Future Oncol; 2020 Jun; 16(17):1189-1198. PubMed ID: 32407173
[No Abstract] [Full Text] [Related]
6. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Kato K; Doki Y; Ura T; Hamamoto Y; Kojima T; Tsushima T; Hironaka S; Hara H; Kudo T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Kitagawa Y
Cancer Sci; 2020 May; 111(5):1676-1684. PubMed ID: 32160365
[TBL] [Abstract][Full Text] [Related]
7. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma.
Hindson J
Nat Rev Gastroenterol Hepatol; 2022 Apr; 19(4):216. PubMed ID: 35292750
[No Abstract] [Full Text] [Related]
9. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Lee J; Kim B; Jung HA; La Choi Y; Sun JM
Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Yamamoto S; Kato K; Daiko H; Kojima T; Hara H; Abe T; Tsubosa Y; Nagashima K; Aoki K; Mizoguchi Y; Kitano S; Yachida S; Shiba S; Kitagawa Y
Future Oncol; 2020 Jul; 16(19):1351-1357. PubMed ID: 32396014
[TBL] [Abstract][Full Text] [Related]
13. Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab.
Sudo K; Kato K; Matsuzaki J; Takizawa S; Aoki Y; Shoji H; Iwasa S; Honma Y; Takashima A; Sakamoto H; Naka T; Sekine S; Boku N; Ochiya T
Jpn J Clin Oncol; 2020 Feb; 50(2):114-121. PubMed ID: 31612917
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
Chin K; Yamamoto S; Takahashi M; Kadowaki S; Kubota Y; Amanuma Y; Okada M; Kanda M; Kimura Y; Nogi Y; Arimitsu Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):302-308. PubMed ID: 36564602
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China.
Lin YT; Liu TX; Chen J; Wang C; Chen Y
Front Public Health; 2022; 10():923619. PubMed ID: 35844891
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
Sun D; Liu D; Liu Q; Hou H
Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
[TBL] [Abstract][Full Text] [Related]
17. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
18. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma.
Peng C; Cohen DJ
Expert Opin Pharmacother; 2021 Jan; 22(1):93-107. PubMed ID: 33034212
[TBL] [Abstract][Full Text] [Related]
19. Frontline nivolumab combinations improve OS in ESCC.
Killock D
Nat Rev Clin Oncol; 2022 Apr; 19(4):219. PubMed ID: 35169266
[No Abstract] [Full Text] [Related]
20. Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma.
Li Y; Yang B; Ma Y; Peng X; Wang Z; Sheng B; Wei Z; Cui Y; Liu Z
Signal Transduct Target Ther; 2021 Nov; 6(1):381. PubMed ID: 34764241
[No Abstract] [Full Text] [Related]
[Next] [New Search]
